uptravi film-coated tablets 400mcg
johnson & johnson international (singapore) pte ltd - selexipag - tablet, film coated - selexipag 0.4 mg
uptravi film-coated tablets 600mcg
johnson & johnson international (singapore) pte ltd - selexipag - tablet, film coated - selexipag 0.6 mg
uptravi film-coated tablets 800mcg
johnson & johnson international (singapore) pte ltd - selexipag - tablet, film coated - selexipag 0.8 mg
coplavix tablets film-coated
sanofi winthrop industrie - clopidogrel, acetylsalicylic acid - tablets film-coated - 75mg+ 100mg
cardiolife tablets coated
arpimed llc - acetylsalicylic acid, magnesium hydroxide - tablets coated - 75mg+ 15,2mg
cardiomagnyl tablets film-coated
takeda gmbh - acetylsalicylic acid, magnesium hydroxide - tablets film-coated - 75mg+ 15.2mg
cardiomagnyl tablets film-coated
takeda gmbh - acetylsalicylic acid, magnesium hydroxide - tablets film-coated - 150mg+ 30,39mg
kengrexal powder for solution
chiesi farmaceutici s.p.a. - cangrelor (cangrelor tetrasodium) - powder for solution - 50mg - cangrelor (cangrelor tetrasodium) 50mg
molita 200mg/25mg modified-release capsules
dr reddy's laboratories (uk) ltd - dipyridamole; aspirin - modified-release capsule - 200mg ; 25mg
clopidogrel bms
bristol-myers squibb pharma eeig - clopidogrel (as hydrogen sulfate) - stroke; peripheral vascular diseases; myocardial infarction; acute coronary syndrome - antithrombotic agents - clopidogrel is indicated in adults for the prevention of atherothrombotic events in:- patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease.- patients suffering from acute coronary syndrome:non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa).st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy.